vs

Side-by-side financial comparison of Costco (COST) and McKesson Corporation (MCK). Click either name above to swap in a different company.

McKesson Corporation is the larger business by last-quarter revenue ($106.2B vs $67.3B, roughly 1.6× Costco). Costco runs the higher net margin — 3.0% vs 1.1%, a 1.9% gap on every dollar of revenue. On growth, McKesson Corporation posted the faster year-over-year revenue change (11.4% vs 8.3%). Costco produced more free cash flow last quarter ($3.2B vs $1.1B). Over the past eight quarters, McKesson Corporation's revenue compounded faster (17.9% CAGR vs 7.9%).

Costco Wholesale Corporation, doing business as Costco, is an American multinational corporation which operates a chain of membership-only big-box warehouse club retail stores. As of 2021, Costco is the third-largest retailer in the world, and as of August 2024, Costco is the world's largest retailer of beef, poultry, organic produce, and wine, with just under a third of American consumers regularly shopping at Costco warehouses.

McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company.

COST vs MCK — Head-to-Head

Bigger by revenue
MCK
MCK
1.6× larger
MCK
$106.2B
$67.3B
COST
Growing faster (revenue YoY)
MCK
MCK
+3.1% gap
MCK
11.4%
8.3%
COST
Higher net margin
COST
COST
1.9% more per $
COST
3.0%
1.1%
MCK
More free cash flow
COST
COST
$2.0B more FCF
COST
$3.2B
$1.1B
MCK
Faster 2-yr revenue CAGR
MCK
MCK
Annualised
MCK
17.9%
7.9%
COST

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
COST
COST
MCK
MCK
Revenue
$67.3B
$106.2B
Net Profit
$2.0B
$1.2B
Gross Margin
13.1%
3.5%
Operating Margin
3.7%
1.5%
Net Margin
3.0%
1.1%
Revenue YoY
8.3%
11.4%
Net Profit YoY
11.3%
34.9%
EPS (diluted)
$4.50
$9.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
COST
COST
MCK
MCK
Q4 25
$67.3B
$106.2B
Q3 25
$86.2B
$103.2B
Q2 25
$63.2B
$97.8B
Q1 25
$63.7B
$90.8B
Q4 24
$62.2B
$95.3B
Q3 24
$93.7B
Q2 24
$58.5B
$79.3B
Q1 24
$58.4B
$76.4B
Net Profit
COST
COST
MCK
MCK
Q4 25
$2.0B
$1.2B
Q3 25
$2.6B
$1.1B
Q2 25
$1.9B
$784.0M
Q1 25
$1.8B
$1.3B
Q4 24
$1.8B
$879.0M
Q3 24
$241.0M
Q2 24
$1.7B
$915.0M
Q1 24
$1.7B
$791.0M
Gross Margin
COST
COST
MCK
MCK
Q4 25
13.1%
3.5%
Q3 25
12.9%
3.4%
Q2 25
13.0%
3.4%
Q1 25
12.5%
4.0%
Q4 24
12.9%
3.4%
Q3 24
3.5%
Q2 24
12.5%
4.0%
Q1 24
12.5%
4.7%
Operating Margin
COST
COST
MCK
MCK
Q4 25
3.7%
1.5%
Q3 25
3.9%
1.4%
Q2 25
4.0%
1.1%
Q1 25
3.6%
1.8%
Q4 24
3.5%
1.3%
Q3 24
0.6%
Q2 24
3.8%
1.3%
Q1 24
3.5%
1.6%
Net Margin
COST
COST
MCK
MCK
Q4 25
3.0%
1.1%
Q3 25
3.0%
1.1%
Q2 25
3.0%
0.8%
Q1 25
2.8%
1.4%
Q4 24
2.9%
0.9%
Q3 24
0.3%
Q2 24
2.9%
1.2%
Q1 24
3.0%
1.0%
EPS (diluted)
COST
COST
MCK
MCK
Q4 25
$4.50
$9.59
Q3 25
$5.87
$8.92
Q2 25
$4.28
$6.25
Q1 25
$4.02
$9.90
Q4 24
$4.04
$6.95
Q3 24
$1.87
Q2 24
$3.78
$7.00
Q1 24
$3.92
$6.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
COST
COST
MCK
MCK
Cash + ST InvestmentsLiquidity on hand
$17.2B
$3.0B
Total DebtLower is stronger
$5.4B
Stockholders' EquityBook value
$30.3B
$-1.3B
Total Assets
$82.8B
$84.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
COST
COST
MCK
MCK
Q4 25
$17.2B
$3.0B
Q3 25
$15.3B
$4.0B
Q2 25
$14.8B
$2.4B
Q1 25
$13.2B
$5.7B
Q4 24
$11.8B
$1.1B
Q3 24
$2.5B
Q2 24
$11.5B
$2.3B
Q1 24
$10.3B
$4.6B
Total Debt
COST
COST
MCK
MCK
Q4 25
$5.4B
Q3 25
$6.0B
Q2 25
$6.5B
Q1 25
$4.5B
Q4 24
$4.4B
Q3 24
$5.7B
Q2 24
$5.6B
Q1 24
$5.6B
Stockholders' Equity
COST
COST
MCK
MCK
Q4 25
$30.3B
$-1.3B
Q3 25
$29.2B
$-1.7B
Q2 25
$27.1B
$-2.0B
Q1 25
$25.6B
$-2.1B
Q4 24
$24.5B
$-3.1B
Q3 24
$-3.0B
Q2 24
$21.8B
$-1.8B
Q1 24
$20.8B
$-2.0B
Total Assets
COST
COST
MCK
MCK
Q4 25
$82.8B
$84.2B
Q3 25
$77.1B
$84.2B
Q2 25
$75.5B
$81.3B
Q1 25
$73.2B
$75.1B
Q4 24
$73.4B
$71.1B
Q3 24
$72.4B
Q2 24
$67.9B
$71.7B
Q1 24
$66.3B
$67.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
COST
COST
MCK
MCK
Operating Cash FlowLast quarter
$4.7B
$1.2B
Free Cash FlowOCF − Capex
$3.2B
$1.1B
FCF MarginFCF / Revenue
4.7%
1.1%
Capex IntensityCapex / Revenue
2.3%
0.1%
Cash ConversionOCF / Net Profit
2.34×
1.04×
TTM Free Cash FlowTrailing 4 quarters
$9.0B
$10.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
COST
COST
MCK
MCK
Q4 25
$4.7B
$1.2B
Q3 25
$3.9B
$2.4B
Q2 25
$3.5B
$-918.0M
Q1 25
$2.7B
$7.7B
Q4 24
$3.3B
$-2.4B
Q3 24
$2.1B
Q2 24
$3.0B
$-1.4B
Q1 24
$731.0M
$4.1B
Free Cash Flow
COST
COST
MCK
MCK
Q4 25
$3.2B
$1.1B
Q3 25
$1.9B
$2.3B
Q2 25
$2.3B
$-1.0B
Q1 25
$1.6B
$7.6B
Q4 24
$2.0B
$-2.5B
Q3 24
$2.0B
Q2 24
$1.9B
$-1.5B
Q1 24
$-300.0M
$4.0B
FCF Margin
COST
COST
MCK
MCK
Q4 25
4.7%
1.1%
Q3 25
2.2%
2.2%
Q2 25
3.7%
-1.1%
Q1 25
2.5%
8.3%
Q4 24
3.2%
-2.6%
Q3 24
2.1%
Q2 24
3.3%
-1.9%
Q1 24
-0.5%
5.2%
Capex Intensity
COST
COST
MCK
MCK
Q4 25
2.3%
0.1%
Q3 25
2.3%
0.1%
Q2 25
1.8%
0.1%
Q1 25
1.8%
0.2%
Q4 24
2.0%
0.1%
Q3 24
0.1%
Q2 24
1.8%
0.1%
Q1 24
1.8%
0.2%
Cash Conversion
COST
COST
MCK
MCK
Q4 25
2.34×
1.04×
Q3 25
1.48×
2.18×
Q2 25
1.82×
-1.17×
Q1 25
1.54×
6.15×
Q4 24
1.81×
-2.71×
Q3 24
8.71×
Q2 24
1.78×
-1.51×
Q1 24
0.42×
5.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

COST
COST

Foods And Sundries$27.1B40%
Non Foods$19.2B28%
Other$12.1B18%
Fresh Foods$9.9B15%
Membership$1.4B2%

MCK
MCK

North American Pharmaceutical Segment$88.3B83%
Oncology And Multispecialty Segment$13.0B12%
Medical Surgical Solutions Segment$3.0B3%
Prescription Technology Solutions Segment$1.5B1%

Related Comparisons